Inozyme Pharma, Inc.
DelistedCIK 1693011fmd_1ZZ2T6401H7NRZM0JKFN1DK9R2Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Mar 31, 2025, 25 periods
Latest annual · FY2024
Millions- Operating income
- (104)
- Net income
- (102)
- Free cash flow
- (92)
Latest quarter · Q1 FY2025
Millions- Operating income
- (28)
- Net income
- (28)
- Free cash flow
- (29)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2019 to FY2024
- n/m
Inozyme Pharma, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$104 million | -$75.6 million | 10-K 2025-03-10 · proof | |
| Net income | -$102 million | -$71.2 million | 10-K 2025-03-10 · proof | |
| Cash from operating activities | -$91.9 million | -$70.7 million | 10-K 2025-03-10 · proof | |
| Free cash flow | -$92 million | -$71 million | 10-K 2025-03-10 · proof | |
| Total assets | $123.2 million | $200.8 million | -38.7% | 10-K 2025-03-10 · proof |
| Total liabilities | $65.4 million | $60.4 million | +8.3% | 10-K 2025-03-10 · proof |
| Cash and cash equivalents | $21.1 million | $34.6 million | -39.1% | 10-K 2025-03-10 · proof |
| Total debt | $46 million | 10-K 2025-03-10 · proof |
- What was Inozyme Pharma, Inc.'s operating income in fiscal 2024?
- Inozyme Pharma, Inc. reported operating income of -$104 million for fiscal 2024 (the year ended Dec 31, 2024), against -$75.6 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What was Inozyme Pharma, Inc.'s net income in fiscal 2024?
- Inozyme Pharma, Inc. reported net income of -$102 million for fiscal 2024 (the year ended Dec 31, 2024), against -$71.2 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What was Inozyme Pharma, Inc.'s cash from operating activities in fiscal 2024?
- Inozyme Pharma, Inc. reported cash from operating activities of -$91.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$70.7 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What was Inozyme Pharma, Inc.'s free cash flow in fiscal 2024?
- Inozyme Pharma, Inc. reported free cash flow of -$92 million for fiscal 2024 (the year ended Dec 31, 2024), against -$71 million the year before. Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What are Inozyme Pharma, Inc.'s total assets?
- As of Dec 31, 2024, Inozyme Pharma, Inc. reported total assets of $123.2 million, against $200.8 million a year earlier (-38.7%). Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What are Inozyme Pharma, Inc.'s total liabilities?
- As of Dec 31, 2024, Inozyme Pharma, Inc. reported total liabilities of $65.4 million, against $60.4 million a year earlier (+8.3%). Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What are Inozyme Pharma, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Inozyme Pharma, Inc. reported cash and cash equivalents of $21.1 million, against $34.6 million a year earlier (-39.1%). Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
- What is Inozyme Pharma, Inc.'s total debt?
- As of Dec 31, 2024, Inozyme Pharma, Inc. reported total debt of $46 million. Source: the 10-K filed with the SEC on Mar 10, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1693011&period_type=annual&limit=5"Information only, not investment advice.